Company Leadership - ALX Oncology appoints Dr Alan Sandler as Chief Medical Officer, leveraging his extensive experience in oncology and drug development to advance the company's clinical programs [1] - Dr Sandler's expertise spans clinical development, regulatory affairs, drug safety, and development strategies, with prior leadership roles at Mirati Therapeutics, Zai Lab, and Genentech [2] - As a former member of ALX Oncology's Board of Directors, Dr Sandler has firsthand knowledge of the company's leadership team and the clinical potential of its lead compound evorpacept [3] Clinical Development - ALX Oncology's lead therapeutic candidate evorpacept is positioned as a cornerstone therapy for the future of immuno-oncology, with ongoing clinical trials across multiple cancer indications [4] - Dr Sandler aims to advance evorpacept into late-stage clinical trials, with the goal of improving patient outcomes across a wide range of tumor types and treatment settings [2][3] Industry Expertise - Dr Sandler brings over 300 co-authored publications, including peer-reviewed articles, reviews, abstracts, and book chapters, reflecting his deep academic and clinical contributions to oncology [3] - His previous roles at Mirati Therapeutics, Zai Lab, and Genentech highlight his leadership in oncology drug development and regulatory strategy, aligning with ALX Oncology's mission to innovate cancer therapies [2]
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer